Systematic De-escalation of Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus Emtricitabine or Lamivudine in Swiss HIV-positive Persons-Reference-Cited by-同舟云学术

Systematic De-escalation of Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus Emtricitabine or Lamivudine in Swiss HIV-positive Persons

Published:2018-12 Issue: Volume:6 Page:21-25
ISSN:2589-5370
Container-title:EClinicalMedicine
language:en
Short-container-title:EClinicalMedicine

Author:

Diaco Natascha D.,Strickler Claudio,Giezendanner Stéphanie,Wirz Sebastian A.,Tarr Philip E.

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. Higher prevalence and faster progression of chronic kidney disease in human immunodeficiency virus-infected middle-aged individuals compared with human immunodeficiency virus-uninfected controls;Kooij;J Infect Dis,2017

2. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents;Bedimo;AIDS,2012

3. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration;Sabin;BMC Med,2016

4. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

5. Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care;HIV/AIDS - Research and Palliative Care;2024-04

2. Efficacy of Lamivudine and Dolutegravir simplification therapy compared with triple therapy in Northeast Brazil (LAMDO Study);Journal of HIV for Clinical and Scientific Research;2024-02-06

3. Development of lipophilic ester prodrugs of dolutegravir for intestinal lymphatic transport;European Journal of Pharmaceutics and Biopharmaceutics;2023-10

4. Need for clear inclusion criteria in reviews of antiretroviral treatments – Authors' reply;The Lancet HIV;2023-03

5. Need for clear inclusion criteria in reviews of antiretroviral treatments;The Lancet HIV;2023-03